With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.

AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.

AstraZeneca said on Monday a mid-stage trial of its cancer drug Enhertu, co-developed with Daiichi Sankyo, showed positive results across multiple HER2-expressing advanced solid tumours in heavily ...

AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu in March 2019 and Datroway (datopotamab deruxtecan) in July 2020, except in Japan where ...

AstraZeneca and Daiichi Sankyo have officially escalated the competition in HER2-positive breast cancer treatment. Thursday, AZ and Daiichi said the FDA has approved their rising star Enhertu for ...

Britain’s cash-strapped Labour government cannot fold to every corporate lobbying campaign. But it ought to heed Soriot and ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu has been approved in the European Union as monotherapy for the treatment of adult patients with advanced non-small ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo Company, Limited (DSKYF.PK) said that enhertu significantly improved progression-free survival in destiny-breast03 head-to-head phase 3 ...

AstraZeneca and Daiichi Sankyo’ s ENHERTU ® has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor- positive, HER2-low or HER2-ultralow ...

ENHERTU ® (fam-trastuzumab deruxtecan-nxki) is the lead product in the ADC Franchise of the Daiichi Sankyo Cancer Enterprise and the most advanced program in AstraZeneca’s ADC scientific platform.